4-氨甲基苄眯二盐酸盐 | 32797-61-8

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨甲基苄眯二盐酸盐
• 中文别名: 4-氨基甲基苯甲酰胺双盐酸盐
• 英文名称: 4-aminomethylbenzamidine
• 英文别名: 4-(aminomethyl)benzenecarboximidamide
• CAS: 32797-61-8
• 化学式: C₈H₁₁N₃
• 分子量: 149.195
• InChiKey: CHOGNBXWAZDZBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  75.9
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2925290090

制备方法与用途

4-氨甲基苄眯二盐酸盐可用作医药合成中间体。若吸入该物质，请将其移至空气新鲜处；若皮肤接触，请脱去污染衣物，并用肥皂水和清水彻底冲洗；如感不适，请及时就医。若眼睛接触到该物质，应分开眼睑，使用流动清水或生理盐水冲洗，并立即寻求医疗帮助。若吞食，请立即漱口，禁止催吐，并尽快就医。

反应信息

• 作为反应物：
  描述：

  4-氨甲基苄眯二盐酸盐 在 盐酸 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Dibasic Inhibitors of Human Mast Cell Tryptase. Part 3: Identification of a Series of Potent and Selective Inhibitors Containing the Benzamidine Functionality

  摘要：

  A survey of charged groups and linkers for a series of symmetrical and unsymmetrical dibasic inhibitors is described. leading to several classes of potent and selective inhibitors. In particular. the benzamidine functionality was identified as the most potent charged group investigated. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00254-2
• 作为产物：
  描述：

  4-(叠氮甲基)苯甲腈 在 palladium on activated charcoal 盐酸 、 氨 、 氢气 作用下， 以 甲醇 、 氯仿 为溶剂， 生成 4-氨甲基苄眯二盐酸盐
  参考文献：
  名称：

  Design, synthesis, and evaluation of oxyanion-hole selective inhibitor substituents for the S1 subsite of factor Xa

  摘要：

  We have designed, synthesized, and evaluated the factor Xa inhibitory activities of p-amidinophenyl-sulfones, amines, and alcohols intended to take advantage of the polarity and hydrogen-bonding potential of the oxyanion hole region of the S1 specificity pocket. We demonstrate that placement of an anionic group within the oxyanion bole region of the catalytic site substantially enhances activity, with small flexible groups favored over bulkier ones. Ab initio pK(a) calculations suggest that the hydroxyl substituent frequently used for benzamidine moieties may be ionized to form an anionic group, consistent with the general trend. One nonamidine based substituent also shows promising activity. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.07.054

文献信息

• [EN] SMALL MOLECULE LFA-1 INHIBITORS<br/>[FR] INHIBITEURS DE LFA-1 À PETITES MOLÉCULES
  申请人：ALLOCYTE PHARMACEUTICALS AG

  公开号：WO2015189265A1

  公开（公告）日：2015-12-17

  The present invention relates to novel compounds which are capable of inhibiting the interaction of LFA-1 with its counter ligands.

  本发明涉及一类新颖的化合物，这些化合物能够抑制LFA-1与其对抗配体的相互作用。
• [EN] INHIBITORS OF FURIN AND OTHER PRO-PROTEIN CONVERTASES<br/>[FR] INHIBITEURS DE FURINE ET AUTRES CONVERTASES DE PRO-PROTÉINES
  申请人：SANFORD BURNHAM MED RES INST

  公开号：WO2013138665A1

  公开（公告）日：2013-09-19

  Disclosed herein are Furin/PC inhibitors for inhibiting Furin and other Propprotein Convertases. Method of making the Furin/PC inhibitors, chemical and biological characterization of the Furin/PC inhibitors, and the use of the Furin/PC inhibitors to treat infectious diseases, cancers, and inflammatory/autoimmune disorders, are also disclosed.

  本文披露了用于抑制Furin和其他Propprotein Convertases的Furin/PC抑制剂。还披露了制备Furin/PC抑制剂的方法，对Furin/PC抑制剂的化学和生物特性进行表征，以及利用Furin/PC抑制剂治疗传染病、癌症和炎症/自身免疫性疾病的用途。
• [EN] ENZYME INHIBITORS<br/>[FR] INHIBITEURS D'ENZYMES
  申请人：KALVISTA PHARMACEUTICALS LTD

  公开号：WO2021032933A1

  公开（公告）日：2021-02-25

  The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, Y, n, R1, R2A, R2B, R3 and *1 are as defined herein.

  本发明提供了如下式(I)的化合物：化合物组合物；在治疗中使用这些化合物；以及使用这些化合物治疗患者的方法；其中A、Y、n、R1、R2A、R2B、R3和*1如本文所定义。
• [EN] 4-AMINOMETHYL BENZAMIDINE DERIVATIVES AND THEIR USE AS FACTOR VIIIA INHIBITORS<br/>[FR] DERIVES DE 4-AMINOMETHYL BENZAMIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DU FACTEUR VIIA
  申请人：HOFFMANN LA ROCHE

  公开号：WO2006027135A1

  公开（公告）日：2006-03-16

  The invention is concerned with novel 4-aminomethyl benzamidine derivatives of formula (I) wherein Ar and X are as defined in the description and in the claims, as well as prodrugs and pharmaceutically acceptable salts thereof. These compounds inhibit the formation of coagulation factors Xa, IXa and thrombin induced by factor VIIa and tissue factor and can be used as medicaments.

  这项发明涉及新颖的式(I)的4-氨甲基苯甲酰胺衍生物，其中Ar和X如描述和索赔中定义，以及它们的前药和药学上可接受的盐。这些化合物抑制由VIIa因子和组织因子诱导的凝血因子Xa、IXa和凝血酶的形成，并可用作药物。
• [EN] MODIFIED RELEASE PHARMACEUTICAL FORMULATION<br/>[FR] FORMULATION PHARMACEUTIQUE À LIBÉRATION MODIFIÉE
  申请人：ASTRAZENECA AB

  公开号：WO2003101424A1

  公开（公告）日：2003-12-11

  A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituents;R2 represents hydrogen, hydroxy, methoxy or ethoxy; andn represents 0, 1 or 2;or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier; provided that the formulation may only contain iota-carrageenan and a neutral gelling polymer when the compound of formula (I) is in the form of a salt; such formulations being of use for the treatment of a cardiovascular disorder.

  一种改良释放的药物组合物，包括以下活性成分：式（I）的化合物，其中R1代表被一个或多个氟取代的C?1-2#191烷基；R2代表氢、羟基、甲氧基或乙氧基；n代表0、1或2；或其药学上可接受的盐；以及药学上可接受的稀释剂或载体；前提是当式（I）的化合物为盐形式时，该配方只能包含碘藻多糖和中性凝胶聚合物；这些配方可用于治疗心血管疾病。